Homepage Top Section2

Xofluza is a first-in-class and single-dose oral medicine with a novel proposed mechanism of action, which restricts polymerase acidic endonuclease, an enzyme required for viral replication. According to

Ci:z is engaged in the development, marketing and distribution of a range of dermocosmetic, cosmetic and skincare products. As per terms of the deal, J&J and its affiliates

The Phase III SOLO-1 trial assessed Lynparza as a maintenance treatment for patients with newly-diagnosed and advanced BRCA-mutated (BRCAm) ovarian cancer, who have been in complete or partial

Earlier this month, the company said that Chronocort could not confirm its superiority over conventional treatment in endocrine control over a 24-hour period, which was the primary objective

Revolution Medicines and Warp Drive Bio are biotechnology firms involved in the studying of molecules and mechanisms of nature to discover first or best-in-class drugs. The deal will

The study has achieved the primary endpoint by demonstrating Kadcyla as a single agent significantly reduced the risk of disease recurrence or death compared to Herceptin as an

The regulator’s Oncologic Drugs Advisory Committee voted unanimously recommending approval of CT-P10, a proposed monoclonal antibody (mAb) biosimilar to Rituxan, to treat adult patients in three proposed indications.

Cinfa Biotech, which was founded in 2013, has offices in Munich, Germany and Pamplona, Spain. The company, which is part of Spanish pharma firm Cinfa Group, is engaged

The trial showed that Stelara induced clinical remission in a significantly greater proportion of UC patients at week 8 compared to placebo at both doses studied. Major secondary